LENZ Therapeutics, Inc. (LENZ)
| Market Cap | 401.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -117.37M |
| Shares Out | 25.53M |
| EPS (ttm) | -15.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $7.21 (45.84%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 160,717 |
| Open | 15.37 |
| Previous Close | 15.40 |
| Day's Range | 15.18 - 16.02 |
| 52-Week Range | 2.01 - 24.59 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.33 (+99.17%) |
| Earnings Date | May 8, 2024 |
About LENZ
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. [Read more]
Analyst Forecast
According to 4 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price forecast is $31.33, which is an increase of 99.17% from the latest price.
News
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidin...
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that...